Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line.

Scientific reports - 11 Mar 2026

Stickler Sandra, Eggerstorfer Marie-Therese, Rieche Maximilian, Arslan Sinem, Teufelsbauer Maryana, Hohenegger Martin, Weigl Lukas, Hamilton Gerhard

Abstract excerpt

Triple negative breast cancer (TNBC) is more chemoresistant and has a poorer prognosis than other breast cancer types. A subset of TNBCs carries KRAS mutations or amplifications. MDA-MB-231 cells, which have a KRAS G13D mutation and express HER2-103, were previously shown to be sensitive to the KRAS G12D inhibitor MRTX1133 and ERBB2-targeting drugs. A kinase inhibitor library of 157 compounds was screened against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodioxoles
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Nitriles

Share to Quinolines

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41813757
DOI: 10.1038/s41598-026-43207-2
PMCID: PMC13102977

Genes

KRAS
MB
ERBB2
BCR
SRC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line.PMID 41813757Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell LinesSemantic proximity Read ↗

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read ↗

Synergistic effects of anlotinib and DDP synergy in breast cancer treatment: inhibiting of cell growth and migration, and augmenting apoptosis and autophagy via modulation of the VEGF/JAK2/STAT3 axisSemantic proximity Read ↗

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.Semantic proximity Read ↗

Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.Semantic proximity Read ↗

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Semantic proximity Read ↗

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Semantic proximity Read ↗

Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.